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ABSTRACT
Background: Non-vitamin K antagonist oral anticoagulants (NOACs) have been included in inter-
national guidelines as important alternatives to vitamin K antagonists (VKAs) for the treatment of ven-
ous thromboembolism (VTE) and stroke prevention in non-valvular atrial fibrillation (NVAF). Meanwhile,
in the Netherlands, NOACs are widely used next to VKAs. The objective of this study is to estimate the
cost-effectiveness of treatment with rivaroxaban compared to VKAs in NVAF and VTE patients in the
Netherlands, using data from international prospective observational phase IV studies.
Methods: Two models were developed to represent NVAF and VTE patients, populated with patients
from the XANTUS (NCT01606995) and XALIA (NCT01619007) international prospective observational
studies. The 1-year cost-effectiveness of rivaroxaban use, compared to VKAs, was explored in a popula-
tion consisting of NVAF and VTE patients (base case) as well as for four scenarios with sub-popula-
tions: NVAF patients only, VTE patients only, NVAF patients with unstable international normalized
ratio (INR), and NVAF patients using an INR self-measuring device.
Results: In the base case, rivaroxaban saved e72,350 and gained 21 quality-adjusted life-years (QALYs)
in a simulation of 2,000 patients over the use of VKAs. Ergo, rivaroxaban was dominant over VKAs. The
probabilistic sensitivity analysis showed a probability of 85% for rivaroxaban being dominant and
100% at a willingness-to-pay threshold of e20,000/QALY. Rivaroxaban appeared to be dominant in all
scenarios as well, except for the NVAF-patients-only scenario where the incremental cost-effectiveness
ratio (ICER) was e157/QALY.
Conclusions: In patients with NVAF or VTE, rivaroxaban treatment is likely to be cost-effective and a
potentially cost-saving alternative to VKA in the Netherlands.
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Atrial fibrillation (AF) and venous thromboembolism (VTE) are
diseases associated with blood clot formation, treated and
prevented with anticoagulation therapy. Vitamin K antago-
nists (VKAs) are mainly used as standard anticoagulation ther-
apy in the Netherlands. Non-vitamin K antagonist oral
anticoagulants (NOACs) have been included in international
guidelines as an important alternative to VKAs. The American
College for Chest Physicians (ACCP) guidelines even sug-
gested the use of NOACs over VKAs for the initial and second-
ary treatment of VTE in patients without cancer1,2. According
to the medical report of the Federation of Dutch Thrombotic
Services (FNT), a total of 465,107 patients are anticoagulated
with either acenocoumarol or phenprocoumon (VKAs). Dutch
reimbursement authorities presume the safety and efficacy of
acenocoumarol, and phenprocoumon is comparable to
warfarin, which is the most used VKA worldwide3. Recent
years, however, have shown a steady increase in patients who
are treated with a NOAC instead of VKAs4.
Non-valvular atrial fibrillation (NVAF) is a disease character-
ized by an irregular heart rate. The arrhythmia is caused by a
“circle stimulus” which leads to uncoordinated atrial activity.
This causes stagnation of the blood flow in the atria, leading
to blood clot formation5. As a result, patients who are diag-
nosed with NVAF have an increased risk of embolic events.
NVAF doubles the risk of heart-related death and is associated
with a 5-fold increased risk of a stroke6. Furthermore, these
clots are also known to block other arteries, causing systemic
embolisms (SE) or myocardial infarctions (MI)7.
VTE is the formation of a blood clot in the veins and can
be sub-divided into deep vein thrombosis (DVT) or pulmon-
ary embolism (PE). Long-term effects of VTE can be post-
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thrombotic syndrome (PTS) and chronic thromboembolic pul-
monary hypertension (CTEPH)8. VKAs, in combination with
low-molecular-weight heparins (LMWH), have been the stand-
ard anticoagulation treatment of VTE patients for decades and
have proven to be very effective in preventing thrombo-
embolic events. However, VKAs have a very narrow thera-
peutic window which can be impacted by many drug and
food interactions. For these reasons VKAs require frequent
monitoring of the international normalized ratio (INR) value of
patients4,9–11. In the Netherlands, the INR measurement is
managed and controlled by anticoagulation clinics.
In the Netherlands, NOACs have become available as a
possible alternative to VKAs for prevention of stroke and
systemic embolism in atrial fibrillation patients in 2012 and
treatment and prevention of VTE in 201512,13. Due to the
predictable kinetics and pharmacodynamics of these drugs,
routine coagulation monitoring is no longer required14.
NOACs have had a prominent place in international guide-
lines for several years1,15. In September 2016, the Dutch asso-
ciation for general practitioners issued a statement stating
that anticoagulant treatment with NOACs is equally adequate
as VKAs concerning the indications AF and VTE11. The FNT
has reported a decrease in the number of patients who
started a VKA for the first time in 2015. As a reason for this
decrease, the FNT states that this is mainly due to the steady
increase in NOAC prescription4.
One of these NOACs, rivaroxaban, has proven to be at least
as effective and safe as VKAs in the ROCKET-AF (NCT00403767)
and EINSTEIN (NCT00440193 and NCT00439777) clinical tri-
als16–19. Recently, also international prospective observational
studies with real-world data (RWD) have been published on
the effectiveness and safety of rivaroxaban. The single-arm
XANTUS (NCT01606995) study included 6,784 patients and
showed low rates of stroke and major bleeding (MB) in AF
patients in routine clinical practice20. The XALIA
(NCT01619007) study included 5,136 patients and examined
the efficacy and safety in VTE patients using rivaroxaban, com-
pared to standard of care in the real-world setting. Results
showed low MB rates in both treatment groups. Moreover, the
use of rivaroxaban was associated with low recurrent VTE rates
and shorter hospitalization compared to standard care in the
real-world setting21.
The objective of this analysis is to estimate the cost-effect-
iveness of treatment with rivaroxaban compared to VKA in
NVAF and LMWH/VKA in VTE patients, using real-world data.
Results will be compared with results from trial-based eco-
nomic analyses.
Methods
For VTE and NVAF patients, two separate models were devel-
oped with a time horizon of 1 year, populated with patients
from two RWD studies of rivaroxaban, XALIA (NCT01619007)
and XANTUS (NCT01606995)20,21. The cost-effectiveness was
explored in five different populations, assuming differences
in costs for these groups: patients with NVAF, patients with
VTE, patients with NVAF as well as patients with VTE,
patients with NVAF who have unstable INR measurements
and NVAF patients using INR self-measuring devices. For
example, the sub-group of unstable NVAF patients is chosen
separately, as these patients can be assumed to have a
higher INR measurement frequency4. Unstable patients were
assumed to have a time in therapeutic range (TTR) of < 60%
which was consistent with 16% of the total hypothetical
population, based on 3,978 patients in the Euro Heart Survey
on AF with complete follow-up22. The hypothetical cohort
Figure 1. Progression-of-disease tree for patients with VTE. The health states for both branches of rivaroxaban and VKA therapy are identical. Abbreviations. DVT,
deep vein thromboembolism; ICH, intracranial haemorrhage; NMCRB, non-major clinically relevant bleeding; PE, pulmonary embolism; PTS, post-thrombotic syn-
drome; VTE, venous thromboembolism.
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was based on previously published trials (XALIA and
XANTUS) and, therefore, a formal ethics review committee
approval and consent of patients was not needed.
VTE model
Figure 1 shows the model for the VTE population. A popula-
tion of 2,000 patients experiencing a VTE event entered the
model and moved to no event, recurrent VTE, non-major
clinically relevant bleeding (NMCRB), MB, intracranial haemor-
rhage (ICH), and death by any cause. Recurrent VTE was sub-
divided into DVT, PE, and DVT which led to PE. Because a
DVT normally first leads to PE before it becomes fatal, the
fatality related to DVT was not taken into account for
DVT&PE patients23. Patients who did not experience a bleed-
ing event, recurrent VTE, or death by any cause were
assumed to be in the no event health state. In the no event
health state it was assumed that 56% of the patients experi-
enced a DVT in the past21. These patients were at risk of PTS.
For PTS, a conservative estimation was made only accounting
for severe PTS at 1% risk for “no event” patients who already
experienced a DVT24. Patients who experienced a PE in the
past could be at risk of developing CTEPH, which was conser-
vatively not taken into account as event rates for PE as well as
CTEPH are low24, especially within the study time horizon.
Patient data from the XALIA study were used to calculate
the relative risks in the model. Death by any cause was
based on the all-cause mortality from the XALIA study21. The
population in the XALIA study treated with rivaroxaban was
on average 59 years of age and 55% male. The population
initially treated with an unfractionated heparin (UFH), LMWH,
or fondaparinux followed by VKA was on average 66 years of
age and 52% male. Due to this difference, a correction was
made using the propensity-scored primary outcomes of the
XALIA study, as shown in Appendix Table A121.
All transition probabilities, for both rivaroxaban and
LMWH/VKA, included in the model are based on the treat-
ment period of 184 days, which is the duration of the XALIA
study. The transition probabilities are summarized in
Appendix Table A2.
NVAF model
The model for NVAF is shown in Figure 2. Data used for the
transition probabilities of AF were corrected to reflect annual
probabilities. Transition probabilities were based on a com-
parison of the XANTUS and ROCKET-AF studies25; therefore,
we only included the health states presented in this com-
parative study. Patient populations of the rivaroxaban arm of
both studies were matched in order to account for the differ-
ences of the real life setting and that of the clinical trial25.
With this correction of the groups, represented as the
Matching Adjusted Indirect Comparison (MAIC ratio), the
rivaroxaban transition probabilities of the ROCKET-AF reflect
the XANTUS results. Application of the MAIC ratio was only
possible for primary end points listed by the study of
Camm25; i.e. ischemic stroke (IS), MB, MI, vascular death,
death by any cause, and no event, as shown in Figure 2.
In the ROCKET-AF study, the control group is treated with
warfarin, which is a VKA that is not available in the
Netherlands. Because therapy with warfarin, acenocoumarol,
and phenprocoumon all depend on dose adjustments based
on patient INR values, their safety and efficacy are consid-
ered the same and, therefore, the ROCKET-AF study data can
be considered reflective of the Dutch situation including the
comparator therapy26. Treatment with rivaroxaban and VKA
were continued during the 1-year time horizon of the model,
which is line with the duration of the XANTUS trial20.
Before adjustment, the rivaroxaban arm of the XANTUS
trial comprised 60.5% of patients aged 75 years or greater
and 25.5% between the age of 65 and 75. Of this same
population, 50.6% had a CHADS2 (Congestive Heart Failure,
Hypertension, Age (75 years), Diabetes Mellitus, prior
Stroke/transient ischemic attack) score of 2, 27.6% had a
score of 3, and 21.8% had a score of 4 or higher25.
The transition probabilities in the NVAF model are shown in
Appendix Table A3.
Costs
In the VTE model, NOAC treatment consisted of a 21-day
course of rivaroxaban, 15mg twice a day, followed by 20mg
once daily10. Costs of the LMWH were based on the costs of
a daily injection of enoxaparin for 5 days, since this was the
most used low-molecular-weight heparin in the RWD stud-
ies21. NVAF patients were treated with 20 or 15mg rivaroxa-
ban once daily27. For both models, the costs of VKAs were
based on a weighted average of the use of acenocoumarol
(5mg) and phenprocoumon (3mg) in 2014, estimated at
Figure 2. Progression-of-disease tree for patients with non-valvular atrial fibril-
lation. The health states for both branches of rivaroxaban and VKA therapy are
identical. Abbreviation. AF, atrial fibrillation.
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77% and 23%, respectively28. All drug costs were based on
the Dutch price list (Z index) excluding 6% VAT29.
Based on the 2015 annual medical report of the FNT, a dis-
tinction was made between measurement at the coagulation
clinic, at home, and self-measurement/self-management4. For
NVAF and VTE the INR should be within the range of 2.0–3.5.
For the events of PE and DVT, the costs of PE alone were
used as a conservative estimate. The costs of a vascular death
were assumed to be equal to the costs of one visit to an
emergency room30. All costs were based on the societal
perspective and corrected to the year 2016. A total overview
of the event-related costs is shown in Table 1.
A complete overview of the utilization and costs associ-
ated with the treatment of VKA and rivaroxaban is shown in
Table 2, as well as the frequency of INR measurements per
year. To calculate the mean number of INR measurements
for stable or unstable NVAF patients in 1 year, the following
formula is used:
The median number of correctly dosed (stable) NVAF
patients is 80.2%4.
A ¼ Total INR control frequency ¼ upper limitlower limitð Þ
80:2%þ lower limit
INR control frequency stable patients ¼ lower limitA
2
þ A





Specific utilities were used for the baseline health state for
patients suffering from NVAF or VTE. The impact of all pos-
sible health states on the patients’ quality-of-life was taken
Table 1. Event costs used in cost-effectiveness analysis.
Event Costs (fixed) Range Source
IS e37,966 Fixed Baeten et al.37
ICH acute e33,378 e19,078–e51,610 Stevanovic et al.38
ICH annually e14,942a Fixed Stevanovic et al.38
MB e5,072 e2,033–e13,847 van Leent et al.39
NMCRB e102 e76–e127 van Leent et al.39
MI e5,117 e5,030–e5,203 Stevanovic et al.40
MI annually e200 e186–e210 Stevanovic et al.40
Severe PTS e25,550 e14,604–e39,507 Stevanovic et al.38
PE e5,071 e2,533–e10,141 van Leent et al.39
DVT e1,592 e796–e3,184 van Leent et al.39
Abbreviations. DVT, deep vein thromboembolism; ICH, intracranial haemor-
rhage; IS, ischemic stroke; MB, major bleeding; MI, myocardial infarction;
NMCRB, non-major clinically relevant bleeding; PE, pulmonary embolism; PTS,
post-thrombotic syndrome.
aAverage of mild, moderate, and severe ICH.
Table 2. Resource utilization and costs of NVAF and VTE.
Parameter Mean Range Source
Number of INR measurements per year
Median 20.80 15.70–27.00 FNT4
Stable patients 20.27 FNT4
Unstable patients 25.97 FNT4
INR measuring costs
First quartile extra costs SM e377.11 Fixed NZa30
Monitoring SM (per quartile) e182.84 Fixed NZa30
INR control (at home) e28.79 Fixed NZa30
INR control (near-patient, per quartile) e190.90 Fixed NZa30
Travelling costs (per km) e0.50 Fixed
Duration of treatment (days)
NOAC for VTE patients 184 Fixed Ageno et al.21
VKA for VTE patients 179 Fixed Ageno et al.21
LMWH for VTE patients 5 Fixed Ageno et al.21
Drug costs
VKA e0.08 Fixed ZiN29
LMWH e10.50 Fixed ZiN41
Rivaroxaban e2.16 Fixed ZiN29
Length of hospitalization (days)
PE; use of LMWH/VKA 7.5 Fixed van Bellen et al.42
PE; use of Rivaroxaban 6.6 Fixed van Bellen et al.42
DVT; use of LMWH/VKA 7.9 Fixed van Bellen et al.42
DVT; use of Rivaroxaban 6.2 Fixed van Bellen et al.42
AF; use of Warfarin 3.02 Fixed Laliberte et al.43
AF; use of Rivaroxaban 2.11 Fixed Laliberte et al.43
Hospitalization costs
Hospitalization costs (per day) e447.07 Fixed Hakkaart-van Roijen et al.31
Outpatient clinic costs (per visit) e80.47 Fixed Hakkaart-van Roijen et al.31
General practitioner (per visit) e33.30 Fixed Hakkaart-van Roijen et al.31
Emergency room visit (per event) 261.38 Fixed Hakkaart-van Roijen et al.31
Group labile INR 16% FNT4
Prevalence DVT within rVTE 56% FNT28
Prevalence PE within rVTE 44% FNT28
LMWH re-treatment (days) 3 FNT4
Abbreviations. AF, atrial fibrillation; DVT, deep vein thrombosis; INR, international normalized ratio;
LMWH, low-molecular-weight heparin; NOAC, non-vitamin K antagonist oral anti-coagulant; NVAF, non-
valvular atrial fibrillation; PE, pulmonary embolism; SM, self-measurement; VKA, vitamin K antagonist;
(r)VTE, (recurrent) venous thromboembolism.
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into account (Table 3). Upon the occurrence of certain events
a (dis)utility for a specific time range was used to calculate
quality-adjusted life-years (QALYs).
Cost-effectiveness analysis
The results of the cost-effectiveness analysis are presented as
the incremental cost effectiveness ratio (ICER) in costs per
QALY. The ICER was calculated for each different population
shown in Table 431. For the base-case scenario, the ICER was
calculated using a weighted average of the VTE and NVAF
population, with 18.75% and 81.25% of patients experiencing
VTE and NVAF, respectively4.
Sensitivity analyses
In order to determine uncertainty around input parameters
we performed a probabilistic sensitivity analysis (PSA). The
distributions applied on the 95% confidence interval (CI) of
the input parameters were beta for probabilities and utilities,
lognormal for relative risks and differences, and gamma for
costs. For the five different populations a PSA was performed
using a Monte Carlo simulation with 2,000 iterations. Results
were plotted in a cost-effectiveness (CE) plane with a willing-
ness-to-pay (WTP) threshold of e20,000/QALY. Results were
used to produce cost-effectiveness acceptability curves
(CEACs). Additionally, a one-way sensitivity analysis was con-
ducted to determine which parameters have the biggest




The deterministic results of the five populations for VKA and
rivaroxaban are shown in Table 5. In the Netherlands a WTP
threshold of e20,000/QALY is used for preventive treatments.
Rivaroxaban was not only cost-effective at this threshold but
even cost-saving in the base case and three other popula-
tions. In the base-case scenario rivaroxaban leads to health
gains of 24 QALYs and savings of e71,923 per 2,000
simulated patients, compared to current standard of care with
VKAs. Rivaroxaban use in scenarios A, C, and D showed a
dominant ICER as well. Rivaroxaban use in NVAF patients only
(scenario B) was the only non-cost-saving scenario, but is still
a cost-effective option with an ICER of e157/QALY.
Sensitivity analyses
For all five populations, a probabilistic sensitivity analysis was
executed with 2,000 iterations. The CE plane for the base
case is shown in Figure 3. The other CE planes are presented
in Appendix Figures A1–A4. Cost-effectiveness acceptability
curves have been established for all five populations. The
probability of being cost-effective at a WTP threshold of
e20,000/QALY is 100% in the base case and all other scen-
arios. When a WTP threshold of e0/QALY is assumed, rivarox-
aban use in the base-case scenario has a probability of
84.0% of being cost-effective compared to VKA treatment.
The probabilities of cost-effectiveness for scenarios A, B, C,
and D were 98.7%, 49.3%, 79.6%, and 98.2% respectively,
at a WTP threshold of e0/QALY. The corresponding cost-
effectiveness acceptability curves (CEAC) are displayed in
Figure 4.
Table 3. Utilities and disutilities used in the cost-effectiveness analysis.
Parameter Mean Range (95% CI) Source
Venous thromboembolism
Baseline utility VTE 0.9000 0.8566–0.9363 van Leent et al.39
(r)DVT (1 month) 0.8000 0.6056–0.9388 van Leent et al.39
Non-fatal PE (1 month) 0.6000 0.3408–0.8316 van Leent et al.39
Major bleeding (14 days) 0.7000 0.5006–0.8658 van Leent et al.39
NMCRB (2 days) 0.7000 0.6848–0.7148 van Leent et al.39
Minor bleeding (5 days) 0.9000 0.8200–0.9583 van Leent et al.39
Disutility severe PTS (lifetime) 0.0700 0.0131–0.1685 Lenert and Soetikno44
Atrial fibrillation
Baseline utility AF 0.6980 0.5542–0.8242 Stevanovic et al.40
Stroke mild 0.6704 0.5337–0.7937 Stevanovic et al.40
Stroke moderate 0.6165 0.4929–0.7328 Stevanovic et al.40
Stroke severe 0.4416 0.3562–0.5287 Stevanovic et al.40
Stroke average 0.5762 Fixed Stevanovic et al.40
Myocardial infarct 0.5328 0.4281–0.6360 Stevanovic et al.40
Disutility other ICH (6 weeks) 0.1385 0.1125–0.1666 Stevanovic et al.40
Disutility of NMCRB (2 days) 0.0600 0.0487–0.0722 Stevanovic et al.40
Medication
Rivaroxaban 0.9730 Ahmad and Lip45
Vitamin K antagonists 0.9480 Robinson et al.46
Abbreviations. AF, atrial fibrillation; (r)DVT, (recurrent) deep vein thrombosis; ICH, intracranial haemorrhage; NMCRB, non-major clinically
relevant bleeding; PE, pulmonary embolism; PTS, post-thrombotic syndrome; VTE, venous thromboembolism.
Table 4. Different populations taken into consideration for the cost-effective-
ness analysis of rivaroxaban vs VKA.




C NVAF without stable INR group (TTR < 60%)
D NVAF only self-measures and self-managers
Abbreviations. INR, international normalized ratio; NVAF, non-valvular atrial
fibrillation; TTR, time in therapeutic range; VTE, venous thromboembolism.
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Results of the one-way sensitivity analysis in the base-case
scenario are shown in Table 6. Tables for scenarios A and B
are displayed in Appendix Tables A4 and A5. In the base-
case scenario, utilities for the use of VKAs and the unit cost
of rivaroxaban were the parameters with the biggest influ-
ence on the ICER.
Discussion
In the base-case analysis, rivaroxaban treatment was associ-
ated with a gain of additional 21 QALYs and saved e72,350
for 2,000 patients over a period of 1 year compared to VKA
treatment. These results suggest that, in the base case,
Table 5. Deterministic costs, effects (2,000 simulations), and incremental cost effectiveness ratios per
patient of the five selected populations.
Costs Effects (QALY) Incremental
SoC Rivaroxaban SoC Rivaroxaban Costs Effects (QALY) ICER
Base-case e1.887.277 e1.815.353 672,911 696,956 –e71.923 24,045 Dominant
Scenario A e3.100.632 e2.704.499 817,92 866,277 –e396.133 48,357 Dominant
Scenario B e1.607.272 e1.610.166 639,447 657,882 e2.894 18,435 e157/QALY
Scenario C e1.677.419 e1.610.166 639,447 657,882 –e67.253 18,435 Dominant
Scenario D e1.789.302 e1.610.166 639,447 657,882 –e179.136 18,435 Dominant























































Figure 4. Cost-effectiveness acceptability curve of the base-case scenario (VTEþNVAF patients) and scenarios A, B, C, and D. Abbreviations. CE, cost-effectiveness;
NVAF, non-valvular atrial fibrillation; QALY, quality-adjusted life-years; VTE, venous thromboembolism.
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rivaroxaban is dominant over the standard treatment with a
VKA for a combined population of patients with NVAF or
VTE. Also in the scenarios including unstable NVAF patients
and NVAF self-measurers/self-managers, the use of rivaroxa-
ban provided cost savings and health gains compared to
VKA treatment. Even though the drug costs of rivaroxaban
are higher than those of VKAs, the total treatment costs are
lower, due to the additional costs for INR monitoring and
the relatively higher bleeding risks associated with VKA treat-
ment. In the total NVAF population, the intervention was
more costly than current treatment, at e2,894, however rivar-
oxaban use is still considered cost-effective with an ICER of
e157/QALY.
To our knowledge this is the first Dutch economic evalu-
ation of rivaroxaban vs VKA based on RWD studies, whereas
most cost-effectiveness studies are based on clinical trial
data. Our model is unique in the fact that it includes VTE
and different NVAF populations in one analysis. The input
parameters for the INR measurement were obtained from
real-life data of the coagulation clinics, as documented in the
FNT report4. Still, there are some uncertainties and limita-
tions to be discussed.
The incidence proportions reported by Ageno et al.21 are
not propensity-score-adjusted, like the hazard ratios.
However, we were unable to use these adjusted values, since
they were only available for MB, recurrent VTE, all-cause mor-
tality, major adverse cardiovascular events, and other
thromboembolic events. The use of relative risks might have
led to an over-estimation of the effect of rivaroxaban, and
therefore an under-estimation of the cost-effectiveness.
The therapeutic and target range for INR in the
Netherlands was not similar to the international range
(2.5–3.5 vs 2.0–3.0). The FNT has recently decided to adjust
the therapeutic INR range to reflect the international val-
ues32. Given this, we assumed that it is not necessary to
extrapolate the INR values from the XANTUS, XALIA, and
ROCKET-AF studies to the Dutch situation. The XANTUS study
has Dutch data available, however it was not suitable for this
analysis because of the absence of a control group. We com-
pared results from the total XANTUS population20 to the
Dutch XANTUS sub-population33, and found the number of
major bleedings and thromboembolic events to be compar-
able (1.9% vs 2.1% and 1.6% vs 1.4%). The number of non-
major bleedings was slightly lower in the total XANTUS
population compared to the Dutch XANTUS sub-population:
12.9% vs 15.8%25,33. More non-major bleedings costs are
higher, which makes the calculated ICER a conserva-
tive outcome.
The XANTUS study did not include a control group20. To
overcome this problem, data from the analysis of Camm
et al.20 were used to make a comparison between the
XANTUS and ROCKET-AF studies16,25. The MAIC ratio was
used to convert transition probabilities of the rivaroxaban
arm from the ROCKET-AF study to resemble the results in
the real world. This leads to an indirect comparison which is
a limitation, but, because there was no control group
included in the XANTUS study, it was the only way to make
a reasonable assumption20. Also, because the study of
Camm25 only included five primary outcomes as stated in
Figure 2, the comparison was limited to these outcomes and
it was not possible to include, for example, the severity of a
stroke or MB (ICH vs non-ICH). These factors might have con-
tributed to either an over- or under-estimation of the ICER in
the NVAF arm of the results. On another note, it can be dis-
cussed that the 1-year time horizon might not be ideal for
modelling a population suffering from NVAF, since this is a
chronic disease requiring lifelong treatment and associated
with significant cardiovascular complications. Therefore, a
model which includes the entire lifespan of the patients suf-
fering from NVAF might give more robust results.
The XALIA study consisted of 184 treatment days (equal
to 6months). It should be stated that 6months of VKA treat-
ment differs from the Dutch guidelines in which 3months of
treatment is recommended for a first episode of recurrent
VTE10. The Dutch guideline for treatment duration of NOACs
is not specific. Therefore, we remained consistent with the 6-
month treatment in the XALIA study, although it might over-
estimate the ICER in the base case and scenario B, mainly
due to increasing incremental costs, driven by the large dif-
ference in drug costs. Since there were no specified costs
available for DVT&PE, a conservative estimation was made to
only account for the costs of a PE, since this was the more
expensive outcome of the two outcomes. This may have
resulted in an under-estimation of the costs of this outcome
and, therefore, an under-estimation of the ICER.
Unfortunately the XANTUS study did not have a sub-group
analysis of Dutch patients, therefore a similar comparison of
outcomes of the NVAF model was not possible.
Table 6. Results of the one-way sensitivity analysis for the base-case scenario.
Lower bound ICER Upper bound ICER
Disease rates VKA—All disease rates VKA Dominant Dominant
Risk ratio rivaroxaban vs VKA—All disease rates VKA e1,194 e3,706
Baseline utilities –e2,695 –e2,649
Utility for diseases –e2,928 Dominant
Utility for the use of rivaroxaban Dominated Dominant
Utility for the use of VKA –e1,238 e5,590
Costs of rivaroxaban Dominant e19
INR measurement –e2,991 Dominant
New patients self-measurers/self-managers (%) –e2,979 Dominant
Disease costs –e1,010 Dominant
Values indicated with a  are located in the southwest quadrant of the cost-effectiveness plane, meaning
rivaroxaban treatment has lower costs and lower health effects than VKA treatment.
Abbreviations. ICER, incremental cost-effectiveness analysis; INR, international normalized ratio; VKA, vitamin
K antagonist.
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The results for the VTE population in this analysis are
comparable with a VTE study done in the UK. In this study
rivaroxaban also proved to be dominant over the standard
treatment in three different treatment durations of 3, 6, and
12months34. Previously, rivaroxaban was already calculated
to be dominant over LMWH/VKA treatment in Dutch VTE
patients, using data from the EINSTEIN clinical trials17–19.
Our results in NVAF patients are more favourable for rivar-
oxaban compared to results from other studies performed in
Belgium and Germany35,36. This might be caused by the fact
that the other studies are both only based on the clinical
trial data from the ROCKET-AF study and that RWD shows a
more positive outcome for rivaroxaban. Another explanation
could be that the drug costs of rivaroxaban have decreased
substantially since these studies were published. This is a
major contributor to the cost of the treatment and, for our
study, we have used a cost of e2.16 per 20mg rivaroxaban,
whereas the Belgian and German studies used e2.70 and
e3.26, respectively29,35,36. The use of e2.16 in this study is
based on data from the Dutch Healthcare institute, which
shows the price before a discount is agreed upon by the
government and the manufacturer29. This makes it a conser-
vative assumption; the price could in fact be lower, leading
to an over-estimation of the ICER13. However, price negotia-
tions regarding the costs associated with the coagulation
clinics occur as well, which could have a negative effect on
the ICER. Moreover, differences between INR values, risk fac-
tors of patients, clinical outcomes, and differences in social
health costs may explain differences of cost-effectiveness
results between countries.
Limitations
As with all cost-effectiveness analyses, this study has its limi-
tations. In the real-world the initial therapy with LMWH in
VTE treated patients might not be necessary, or needs to be
prolonged, which is not taken into account. Moreover, treat-
ment interruption, treatment switch, or permanent discon-
tinuation was not taken into account. Furthermore, the
health states in the model were based on the measured out-
comes included in the XANTUS and XALIA trials21,25, which
were much less explicit than the outcomes included in the
trials16–18. In the NVAF model we included the health state
“vascular death”, while not taking into account whether this
death was caused by MI or IS. Since costs related to the
patient’s death might differ by cause of vascular death, this
is a limitation of our model. Another point of discussion is
the difference in definition of MB between the NVAF and
VTE model. The XANTUS study used International Society of
Thrombosis and Haemostasis (ISTH) criteria as definition for
MB25, while the XALIA study defined MB as
overt bleeding associated with a fall in haemoglobin of 20g/L or
more; a transfusion of two or more units of packed red blood cells or
whole blood; critical site bleeding (intracranial, intraspinal, intraocular,
pericardial, intra-articular, intramuscular with compartment
syndrome, and retroperitoneal); or fatal bleeding [e14]21.
In the model we applied the same costs for both defini-
tions, which might have led to over- or under-estimation of
the ICER. Second, MB may differ between the VTE and NVAF
models, since patient characteristics were based on the pop-
ulations included in the XALIA and XANTUS trials, wherefore
risk factors for bleeding events may differ between these
populations. Last, we did not make a distinction between dif-
ferent sorts of MB. In NVAF patients, rivaroxaban is associ-
ated with decreased risk of ICH, but an increased risk of non-
ICH. ICH is associated with very high (long-term) costs. Since
rivaroxaban would prevent higher costs, this is a conservative
assumption. Nevertheless, varying risks of MB in the one-way
sensitivity analysis still showed the ICER to be cost-effective.
Conclusions
In conclusion, treatment with rivaroxaban was cost-effective
or even cost-saving and provided health gains compared to
the standard treatment with a VKA in Dutch NVAF and VTE
patients, as well as the other examined scenarios including
only VTE patients (A), only NVAF patients (B), unstable NVAF
patients (C), and NVAF self-measurers (D). In the first year of
treatment, rivaroxaban showed higher benefit for VTE than
NVAF patients. In sensitivity analysis, the model has shown
to be robust. At a WTP threshold of e20,000/QALY, rivaroxa-
ban appeared to be 100% cost-effective in all scenarios.
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Appendix
Table A1. XALIA treatment-emergent clinical outcome results with propensity score adjustment.
Type of event Rivaroxaban (n¼ 2,505) SoC (n¼ 2,010) Source
Major bleeding 19 (0.8%) 43 (2.1%) Ageno et al.21
Recurrent venous thromboembolism 36 (1.4%) 47 (2.3%) Ageno et al.21
All-cause mortality 11 (0.4%) 69 (3.4%) Ageno et al.21
Major adverse cardiovascular events 9 (0.4%) 12 (0.6%) Ageno et al.21
Other thromboembolic events 4 (0.2%) (0.3%) Ageno et al.21
Abbreviation. SoC, Standard of Care.
Table A2. Transition probabilities used in the VTE model.
Transition probability Value (95% CI/range) Distribution Source
Rivaroxaban Vitamin K-antagonists
Recurrent VTE and VTE related deaths
rVTE 0.0140 (0.0098–0.0190) 0.0230 (0.0169–0.0300) Beta Ageno et al.21
non-fatal PE 0.0060 (0.0034–0.0094) 0.0071 (0.0039–0.0112) Beta Ageno et al.21
fatal PE 0.0010 (0.0002–0.0026) 0.0009 (0.0001–0.0026) Beta Ageno et al.21
DVT 0.0050 (0.0026–0.0081) 0.0124 (0.0080–0.0177) Beta Ageno et al.21
DVT & PE 0.0010 (0.0002–0.0026) 0.0018 (0.0004–0.0040) Beta Ageno et al.21
Bleeding events
MB 0.0080 (0.0049–0.0118) 0.0210 (0.0152–0.0277) Beta Ageno et al.21
Non-fatal MB 0.0080 (0.0049–0.0118) 0.0201 (0.0144–0.0267) Beta Ageno et al.21
Fatal MB 0.0000 0.0009 Fixed Ageno et al.21
NMCRB 0.1140 (0.1021–0.1264) 0.1010 (0.0886–0.1141) Beta Ageno et al.21
ICH 0.0020 (0.0007–0.0040) 0.0020 (0.0006–0.0043) Beta Ageno et al.21
Secondary outcomes
No event 0.8580 0.8190 Fixed Ageno et al.21
PTS given no event 0.0056 0.0056 Fixed Kahn and Ginsberg24
Death any cause 0.0040 (0.0019–0.0068) 0.0340 (0.0265–0.0423) Beta Ageno et al.21
Abbreviations. DVT, deep venous thromboembolism; ICH, intracranial haemorrhage; MB, major bleeding; NMCRB,
non-major clinically relevant bleeding; PE, pulmonary embolism; rVTE, recurrent venous thromboembolism; VTE, ven-
ous thromboembolism.
TABLE A3. Transition probabilities used in the NVAF model.
Transition probability Value (95% CI/range) Distribution Source
Warfarin Rivaroxaban
No event 0.9151 0.9251 Fixed Camm25
IS 0.0196 (0.0165–0.0230) 0.0150 (0.0123–0.0180) Beta Camm25
MI 0.0112 (0.0089–0.0138) 0.0075 (0.0056–0.0096) Beta Camm25
MB 0.0340 (0.0299–0.0383) 0.0310 (0.0271–0.0351) Beta Camm25
Vascular death 0.0171 (0.0142–0.0202) 0.0182 (0.0152–0.0215) Beta Camm25
Death any cause 0.0030 (0.0019–0.0044) 0.0033 (0.0021–0.0047) Beta Camm25
Abbreviations. IS, ischemic stroke; MI, myocardial infarction; MB, major bleeding.
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Table A5. Results of the one-way sensitivity analysis for scenario B.
Lower bound ICER Upper bound ICER
Disease rates VKA – Major bleed e255 e51
Disease rates VKA – Stroke e1,627 Dominant
Disease rates VKA – MI e466 Dominant
Disease rates VKA – All disease rates VKA e1,954 Dominant
Risk ratio Rivaroxaban vs VKA – Major bleed Dominant e1,496
Risk ratio Rivaroxaban vs VKA – Stroke Dominant e8,219
Risk ratio Rivaroxaban vs VKA – MI Dominant e1,336
Risk ratio Rivaroxaban vs VKA – All disease rates VKA e696 e7,008
Baseline utility AF e198 e133
Utility for diseases e152 e162
Utility for the use of Rivaroxaban Dominated e78.88
Utility for the use of VKA e57 Dominated
Costs of Rivaroxaban Dominant e4,434
New patients self-measurers/self-managers (%) e177 e137
Disease costs e1,820 Dominant
Values indicated with a  are located in the southwest quadrant of the cost-effectiveness plane, meaning
Rivaroxaban has lower costs and lower health effects than VKAs.
Abbreviations. AF, atrial fibrillation; ICER, incremental cost-effectiveness ratio; VKA, vitamin K antagonist.
Table A4. Results of the one-way sensitivity analysis for scenario A.
Lower bound ICER Upper bound ICER
Disease rates VKA – Major bleed Dominant Dominant
Disease rates VKA – NMCR bleeding Dominant Dominant
Disease rates VKA – Intracranial bleeding Dominant Dominant
Disease rates VKA – All disease rates VKA Dominant Dominant
Risk ratio Rivaroxaban vs VKA – Major bleed Dominant Dominant
Risk ratio Rivaroxaban vs VKA – NMCR bleeding Dominant Dominant
Risk ratio Rivaroxaban vs VKA – Intracranial bleeding Dominant Dominant
Risk ratio Rivaroxaban vs VKA – All disease rates VKA Dominant Dominant
Baseline utility norm population Dominant Dominant
Utility for diseases Dominant Dominant
Utility for the use of Rivaroxaban e23,812/QALY Dominant
Utility for the use of VKA Dominant Dominant
Costs of Rivaroxaban Dominant Dominant
INR measurement Dominant Dominant
New patients self-measurers/self-managers (%) Dominant Dominant
Disease costs Dominant Dominant
Values indicated with a  are located in the southwest quadrant of the cost-effectiveness plane, meaning
Rivaroxaban has lower costs and lower health effects than VKAs.
Abbreviations. ICER, incremental cost-effectiveness ratio; INR, international normalized ratio; NMCR, non-major



















CE plane population A
Figure A1. Probabilistic sensitivity analysis of population A, venous thromboembolism. Abbreviations. CE, cost-effectiveness; QALY, quality adjusted life-year.
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CE plane population B
Figure A2. Probabilistic sensitivity analysis of scenario B, non-valvular atrial fibrillation. Abbreviations. CE, cost-effectiveness; QALY, quality adjusted life-year.
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Figure A4. Probabilistic sensitivity analysis of population D, NVAF only self-measures and self-managers. Abbreviations. CE, cost-effectiveness; QALY, quality
adjusted life-year.
318 L. A. DE JONG. ET AL.
